Acrivon Therapeutics reported net income of -$18.00M for the quarter ended Jun 2026. This income statement covers 20 quarters of results from Sep 2021 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 1.77M | 1.77M | 1.77M | 1.77M | 1.78M | 4.12M | 21.92M | 22.07M | 22.10M | 22.52M | 22.64M | 30.97M | 31.13M | 31.23M | 31.35M | 31.45M | 31.55M | 31.65M | 38.75M | 42.85M |
| Operating items | ||||||||||||||||||||
| Research & DevelopmentR&D | 18.45M | 9.76M | 10.52M | 10.27M | 15.48M | 11.47M | 15.03M | 18.86M | 18.63M | 15.41M | 16.18M | 13.65M | 14.75M | 15.17M | 13.84M | |||||
| Selling, General & AdministrativeSG&A | 4.63M | 5.00M | 5.87M | 5.58M | 6.20M | 6.41M | 6.28M | 6.32M | 6.25M | 6.47M | 6.04M | 5.37M | 4.74M | 4.82M | ||||||
| Other Operating ExpensesOther Opex | 2.67M | 4.27M | 7.21M | 5.92M | 9.57M | -8.50M | ||||||||||||||
| Operating ExpensesOpex | 2.67M | 4.27M | 7.21M | 5.92M | 9.57M | 9.95M | 14.39M | 15.52M | 16.14M | 21.05M | 17.67M | 21.44M | 25.14M | 24.95M | 21.66M | 22.65M | 19.69M | 20.12M | 19.90M | 18.67M |
| Operating IncomeOp. Inc | -2.67M | -4.27M | -7.21M | -5.92M | -9.57M | -9.95M | -14.39M | -15.52M | -16.14M | -21.05M | -17.67M | -21.44M | -25.14M | -24.95M | -21.66M | -22.65M | -19.69M | -20.12M | -19.90M | -18.67M |
| EBIT | -2.67M | -4.27M | -7.21M | -5.92M | -9.57M | -9.95M | -14.39M | -15.52M | -16.14M | -21.05M | -17.67M | -21.44M | -25.14M | -24.95M | -21.66M | -22.65M | -19.69M | -20.12M | -19.90M | -18.67M |
| Non-operating items | ||||||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 1.81M | 1.77M | 1.77M | 1.69M | 1.45M | 2.69M | 2.70M | 2.36M | 2.00M | 1.73M | 1.51M | 1.25M | 0.99M | 0.86M | ||||||
| Other Non Operating IncomeOther Non Op Inc. | -0.00M | -0.02M | -0.01M | 0.10M | 0.38M | 1.03M | -0.17M | -0.16M | -0.10M | 0.11M | -0.26M | -0.06M | 0.00M | -0.24M | -0.01M | -0.09M | -0.05M | -0.12M | -0.13M | -0.16M |
| Non Operating IncomeNon Op. Inc. | 0.23M | -0.07M | -0.01M | 0.10M | 0.38M | 1.02M | 1.64M | 1.61M | 1.67M | 1.80M | 1.18M | 2.64M | 2.70M | 2.12M | 1.98M | 1.64M | 1.45M | 1.13M | 0.86M | 0.70M |
| Net income details | ||||||||||||||||||||
| EBT | -2.67M | -4.27M | -7.21M | -5.92M | -9.57M | -9.95M | -12.59M | -13.75M | -14.37M | -19.36M | -16.22M | -18.74M | -22.44M | -22.59M | -19.67M | -20.92M | -18.18M | -18.87M | -18.91M | -17.81M |
| Profit After TaxPAT | -2.44M | -4.34M | -7.22M | -5.82M | -9.33M | -8.89M | -12.76M | -13.91M | -14.47M | -19.06M | -16.49M | -18.80M | -22.44M | -22.88M | -19.68M | -21.18M | -18.23M | -18.99M | -19.04M | -18.00M |
| Income from Non-Controlling InterestsInc. Minority | -2.44M | -4.34M | -7.22M | -5.82M | -9.33M | -8.89M | -12.65M | -14.35M | ||||||||||||
| Income from Continuing OperationsIncome (Continuing) | -2.67M | -4.27M | -7.21M | -5.92M | -9.57M | -9.95M | -12.59M | -13.75M | -14.37M | -19.36M | -16.22M | -18.74M | -22.44M | -22.59M | -19.67M | -20.92M | -18.18M | -18.87M | -18.91M | -17.81M |
| Consolidated Net IncomeConsol Net Inc. | -2.67M | -4.27M | -7.21M | -5.92M | -9.57M | -9.95M | -12.59M | -13.75M | -14.37M | -19.36M | -16.22M | -18.74M | -22.44M | -22.59M | -19.67M | -20.92M | -18.18M | -18.87M | -18.91M | -17.81M |
| Income towards Parent CompanyParent Net Inc | -2.67M | -4.27M | -7.21M | -5.92M | -9.57M | -9.95M | -12.59M | -13.75M | -14.37M | -19.36M | -16.22M | -18.74M | -22.44M | -22.59M | -19.67M | -20.92M | -18.18M | -18.87M | -18.91M | -17.81M |
| Net Income towards Common StockholdersNet Income | -2.67M | -4.27M | -7.21M | -5.92M | -9.57M | -9.95M | -12.59M | -13.75M | -14.37M | -19.36M | -16.22M | -18.74M | -22.44M | -22.59M | -19.67M | -20.92M | -18.18M | -18.87M | -18.91M | -17.81M |
| Additional items | ||||||||||||||||||||
| EPS (Basic) | -1.51 | -2.45 | -4.08 | -3.35 | -5.38 | -2.41 | -0.57 | -0.63 | -0.65 | -0.88 | -0.72 | -0.52 | -0.59 | -0.67 | -0.51 | -0.54 | -0.47 | -0.49 | -0.49 | -0.43 |
| EPS (Diluted) | -1.51 | -2.45 | -4.08 | -3.35 | -5.38 | -2.41 | -0.57 | -0.63 | -0.65 | -0.88 | -0.72 | -0.52 | -0.59 | -0.67 | -0.51 | -0.54 | -0.47 | -0.49 | -0.49 | -0.43 |
| Shares Outstanding | 1.77M | 1.74M | 1.77M | 1.77M | 1.78M | 4.12M | 21.92M | 21.97M | 22.08M | 22.08M | 22.59M | 36.13M | 38.11M | 33.79M | 38.35M | 38.46M | 38.56M | 38.51M | 38.72M | 41.84M |
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 1.77M | 1.74M | 1.77M | 1.77M | 1.78M | 4.12M | 21.92M | 21.97M | 22.08M | 22.08M | 22.59M | 36.13M | 38.11M | 33.79M | 38.35M | 38.46M | 38.56M | 38.51M | 38.72M | 41.84M |
| EBITDA | -2.67M | -4.27M | -7.21M | -5.92M | -9.57M | -9.95M | -14.39M | -15.52M | -16.14M | -21.05M | -17.67M | -21.44M | -25.14M | -24.95M | -21.66M | -22.65M | -19.69M | -20.12M | -19.90M | -18.67M |